Robinson Rachel C, Taylor Ashley N, Cato Amy W, Patel Vijay S, Waller Jennifer L, Wayne Nathaniel B
Department of Pharmacy, Wellstar MCG Health, Augusta, GA, USA.
Department of Respiratory Therapy, Wellstar MCG Health, Augusta, GA, USA.
J Pharm Pract. 2025 Jun;38(3):299-304. doi: 10.1177/08971900241285248. Epub 2024 Sep 20.
Patients maintained on extracorporeal membrane oxygenation (ECMO) often require systemic anticoagulation to prevent circuit clotting and systemic thromboembolic complications. The optimal intensity of anticoagulation to balance the risk of bleeding and prevention of thrombotic complications in this patient population is not well described. To compare bleeding events in patients on ECMO anticoagulated with standard vs low intensity heparin protocols. This single-center, retrospective cohort study included adult patients on VA- or VV-ECMO and anticoagulated with low or standard intensity heparin protocols. The primary outcome was the incidence of major bleeding; secondary outcomes included the incidence of minor bleeding, thrombotic complications, heparin-induced thrombocytopenia, in-hospital mortality, time in therapeutic range, anti-Xa correlation with aPTT, intensive care unit and hospital lengths of stay, oxygenator exchanges, and rate of protocol switching. A total of 27 patients (14 low intensity, 13 standard intensity) were included. There were six major bleeding events in the low intensity group and four in the standard intensity group ( = 0.69); there were four minor bleeding events in the low intensity group and five in the standard intensity group ( = 0.69). Seven patients in the standard intensity group switched protocols; zero patients in the low intensity group switched protocols ( = 0.002). There were no differences in any other outcomes. There was no difference in the incidence of any bleeding or thrombotic events when using a low vs standard intensity heparin protocol in patients on ECMO. A low intensity heparin strategy for patients on ECMO may be feasible and safe.
接受体外膜肺氧合(ECMO)治疗的患者通常需要进行全身抗凝,以防止体外循环回路凝血和全身性血栓栓塞并发症。目前对于该患者群体中平衡出血风险与预防血栓形成并发症的最佳抗凝强度尚无明确描述。为比较接受标准肝素方案与低强度肝素方案抗凝的ECMO患者的出血事件。这项单中心回顾性队列研究纳入了接受VA-ECMO或VV-ECMO治疗且采用低强度或标准强度肝素方案抗凝的成年患者。主要结局是大出血的发生率;次要结局包括小出血的发生率、血栓形成并发症、肝素诱导的血小板减少症、住院死亡率、处于治疗范围内的时间、抗Xa与活化部分凝血活酶时间(aPTT)的相关性、重症监护病房和医院住院时间、氧合器更换以及方案转换率。共纳入27例患者(14例低强度组,13例标准强度组)。低强度组有6例大出血事件,标准强度组有4例(P = 0.69);低强度组有4例小出血事件,标准强度组有5例(P = 0.69)。标准强度组有7例患者更换了方案;低强度组无患者更换方案(P = 0.002)。其他任何结局均无差异。在接受ECMO治疗的患者中,使用低强度肝素方案与标准强度肝素方案相比,任何出血或血栓形成事件的发生率均无差异。对于接受ECMO治疗的患者,低强度肝素策略可能是可行且安全的。